Skip to main content

Mortality Higher for COVID-19 Hospitalization Than for Flu in 2023/2024 Season

Medically reviewed by Carmen Pope, BPharm. Last updated on May 22, 2024.

By Lori Solomon HealthDay Reporter

WEDNESDAY, May 22, 2024 -- In fall/winter 2023/2024, the risk for death in patients hospitalized for COVID-19 was greater than the risk for death in patients hospitalized for seasonal influenza, according to a research letter published online May 15 in the Journal of the American Medical Association.

Yan Xie, Ph.D., from the Veterans Affairs St. Louis Health Care System, and colleagues evaluated the risk for death in a cohort of people hospitalized for COVID-19 (8,625 individuals) or seasonal influenza (2,647 individuals) in fall/winter 2023/2024. The analysis included data identified from the U.S. Department of Veterans Affairs electronic health records.

The researchers found that patients hospitalized for COVID-19 had a higher risk for death versus those hospitalized for seasonal influenza (adjusted death rate, 5.70 versus 4.24 percent at 30 days; adjusted hazard ratio [HR], 1.35; 95 percent confidence interval [CI], 1.10 to 1.66). There were no significant differences in the risk for death among people hospitalized for COVID-19 before and during the JN.1-predominant era (adjusted death rate, 5.46 versus 5.82 percent at 30 days; adjusted HR, 1.07; 95 percent CI, 0.89 to 1.28).

"The findings should be interpreted in the context of nearly twice as many hospitalizations for COVID-19 compared with seasonal influenza during 2023-2024," the authors write.

One author disclosed receiving fees from Guidepoint.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted May 2024

Further Support and Information on COVID-19

Read this next

Residual Risk Seen for Death, Postacute Sequelae in Third Year After COVID-19 Hospitalization

THURSDAY, June 13, 2024 -- For individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the risks for death and postacute sequelae of COVID-19...

Systemic Side Effects of COVID-19 Vaccine Tied to Greater nAB Response

TUESDAY, June 11, 2024 -- Short-term systemic side effects of the severe acute respiratory coronavirus 2 (SARS-CoV-2) mRNA vaccine are associated with greater long-lasting...

Nirmatrelvir-Ritonavir No Aid for Long COVID Symptoms

MONDAY, June 10, 2024 -- A 15-day course of nirmatrelvir-ritonavir (NMV/r) is safe but does not demonstrate a significant benefit for improving postacute sequelae of SARS-CoV-2...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.